Characterisation and management of differentiated thryoid cancer in South Africa

SAFER-LowDTC: South Africa Evaluating Radioactive Iodine De-escalation in Low-Risk Differentiated Thyroid Cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

PACTR

Registry ID

PACTR202606600099760

Enrollment

100

Registered

2026-06-19

Start date

2026-06-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

Omission of radioactive iodine therapy

Radioactive iodine therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Age =18 years • Histologically proven well-differentiated thyroid carcinoma • Low-risk category per ATA 2015 classification • ECOG performance status 0–2

Exclusion criteria

Exclusion criteria: • Pregnant or breastfeeding women • Poorly differentiated or anaplastic thyroid cancer • Recent non-thyroid malignancy (<2 years in remission), • Any disorder that may compromise compliance with study procedures especially psychiatric conditions.

Design outcomes

Primary

Measure	Time frame
Disease-free survival (DFS), defined by the absence of anatomic, functional, and/or biochemical evidence of disease.	—

Secondary

Measure	Time frame
Response to therapy, quality of life assessment.	—

Countries

South Africa

Contacts

Public ContactAkinwale Ayeni

Division of Nuclear Medicine University of the Watersrand

akinwale.ayeni@wits.ac.za+27744326507

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026